← DPP-4 inhibitors × quality of life & behaviour

SynthesisPharmacology2010

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

Walid K H Fakhoury et al.PubMed ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with higher quality of life & behaviour

2.6×1.2× to 5.3×

Bigger than 9 in 10 on the map

As reported

RR 2.56, 95% CI 1.23–5.33

Correlation, not cause

Went with higher quality of life & behaviour

2.4×1.3× to 4.1×

Bigger than 9 in 10 on the map

As reported

RR 2.40, 95% CI 1.30–4.11

Two numbers in the abstract

the abstract, start to end

… with the use of sitagliptin (RR = 2.56, 95% CI = 1.23-5.33, p = 0.01) and exenatide (RR = 2.40, 95% CI = 1.30-4.11, p = …

← favours treatmentfavours comparator →
could be chance
Quality of life & behaviour
RR 2.561.23–5.33
Quality of life & behaviour
RR 2.401.30–4.11
GLP-1 receptor agonistsDPP-4 inhibitorsQuality of life & behaviour
1 / 3

42 papers cite it

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
this paperpooled ittrialcites it

The trial

NCT06894784phase 336 enrolled2025
Full record →Abstract, authors, funding and every citing paper · PMID 20616619